Status:
COMPLETED
Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer Female
Eligibility:
FEMALE
39-74 years
Phase:
PHASE2
Brief Summary
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection ...
Detailed Description
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study seeks to understand the nature of the phenomenon of personalized cancer risk rejection in the context of mammog...
Eligibility Criteria
Inclusion
- Female sex
- Age 39-74 (i.e., people who are eligible for routine breast cancer screening and for whom guidelines recommend an informed, risk-based decision)
- English literacy
- Black or African American race
Exclusion
- 1\. Prior diagnosis of
- breast cancer
- Ductal carcinoma in situ (DCIS)
- Lobular carcinoma in situ (LCIS)
- Known BRCA1/2 gene mutation
- Cowan syndrome
- Li-Fraumeni syndrome
- Having received previous chest radiation for treatment of Hodgkin's lymphoma.
Key Trial Info
Start Date :
April 16 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2025
Estimated Enrollment :
781 Patients enrolled
Trial Details
Trial ID
NCT06975085
Start Date
April 16 2025
End Date
April 30 2025
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado
Aurora, Colorado, United States, 80045